Embryonal rhabdomyosarcoma accounts for 57% of all rhabdomyosarcoma cases, and embryonal rhabdomyosarcoma predominates in children under 5 years of age with rhabdomyosarcoma, which is the best prognostic type of rhabdomyosarcoma. Embryonal rhabdomyosarcoma does not necessarily indicate a maternal fetal origin. Rhabdomyosarcoma develops from abnormal development of early muscle cells. The exact cause of the development remains unclear, but may be related to genetic factors, chromosomal abnormalities, and gene fusions. Some specific genes or chromosomal abnormalities are known to be associated with the development of rhabdomyosarcoma, such as heterozygous deletion of chromosome 11 in some embryonal rhabdomyosarcomas and chromosomal translocations in some adenoid rhabdomyosarcomas, such as chromosomes 2 and 13 and 1 and 13 forming the corresponding fusion genes PAX3 and PAX7, respectively. in addition, some genetic disorders and congenital syndromes, such as Leveraumeni cancer susceptibility syndrome, type I neurofibromatosis, and Bevi syndrome, are also associated with an increased risk of developing rhabdomyosarcoma. However, it is important to note that this only explains a very small number of cases. Embryonal rhabdomyosarcoma is also a malignant tumor, and only a few cases develop in association with chromosomal and genetic abnormalities.